Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp86 | Diabetes (1) | ECE2016

Novel biomarkers of chronic kidney disease in diabetes

Zuraeva Zamira , Mikhaleva Olga , Vikulova Olga , Ilyin Aleksandr , Shamkhalova Minara , Shestakova Marina , Dedov I.I.

Background and aims: Microalbuminuria (MA) is not specific predictor of early stages of chronic kidney disease (CKD) in diabetes. We investigate several markers that might be useful in assessing early kidney damage in T1DM and T2DM patients additional to MA.Materials and methods: We examined 111 patients (T1DM/T2DM: 51/60) with AER<20 mg/l (n=80); <199 mg/l (n=18); ≥200 mg/l (n=13). Biomarkers of kidney damage (c...

ea0049ep568 | Diabetes complications | ECE2017

Tubular and glomerular biomarkers of kidney injury on glucagon-like peptide-1 (GLP-1) therapy in type 1 diabetic patients

Zuraeva Zamira , Vikulova Olga , Mikhaleva Olga , Shestakova Marina , Ilyin Aleksandr , Shamkhalova Minara , Dedov Ivan

Background and aims: To evaluate the level of tubular and glomerular biomarkers of kidney injury as potential nephroprorotective effects of GLP-1R agonist (liraglutide) addition in type 1 diabetic patients compared to standard insulin therapy.Materials and methods: 12 T1DM patients with normo-(AER <20 mg/l, n=7) and microalbuminuria (AER<199 mg/l, n=5) with liraglutide 1.2 mg as add on to insulin for 6 month and 12 patients with...

ea0041ep484 | Diabetes complications | ECE2016

Association of the PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, Lipc C(-514)T, Ace I/D, Slco1b1 Val174ala polymorphism with endothelial function and atorvastatin response in type 2 diabetic patients

Lebedeva Nadezhda , Vikulova Olga , Nikitin Alexei , Shamkhalova Minara , Shestakova Marina , II Dedov

Aim: To assess the association of the endothelial dysfunction (ED) parameters and the lipid-lowering response to atorvastatin therapy in patients with T2D with genetic markers of inflammation.Methods: We include 97 T2D patients with first prescribed atorvastatin 10–20 mg: M/F 26/71; mean age 57 years. After 12 month of statin therapy, patients had fasting lipid profiles and ED parameters repeated. For ED evaluation, we performed pulse wave analysis ...

ea0041ep541 | Diabetes therapy | ECE2016

PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, LIPC C(-514)T, ACE I/D, SLCO1B1 Val174Ala polymorphism as predictors of lipid-lowering response to statin therapy in patients with T2DM

Lebedeva Nadezhda Ol , K Vikulova Olga , Nikitin Alexei G , Shamkhalova Minara Sh , Shestakova Marina V

Aim: To evaluate the effect of PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, LIPC C(-514)T, ACE I/D, SLCO1B1 Val174Ala polymorphism on the response to statins therapy in patients with type 2 diabetes mellitus (T2DM).Methods: We consecutively recruited patients with type 2 DM requiring lipid-lowering therapy according to current guidelines. Patients were started on either atorvastatin 10 or 20 mg. After 12 month of st...

ea0073pep8.7 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Russian hypothalamic and pituitary tumor registry (OGGO): current results

Lutsenko Alexander , Przhiyalkovskaya Elena , Belaya Zhanna , Vikulova Olga , Pigarova Ekaterina , Zenkova Tatiana , Mamedova Elizaveta , Grebennikova Tatiana , Dzeranova Larisa , Rozhinskaya Liudmila , Marova Evgenia

BackgroundPituitary disease registries are major instruments of epidemiological and clinical data collection used worldwide.ObjectiveTo assess the data of pituitary tumor registry in Russia.Material and methodsPatient records, retrieved from online platform of the Registry.ResultsCurrently there are 9858 patients regis...